Volume 24, Issue 1 (2021)                   mjms 2021, 24(1): 45-54 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

alizadeh R, Azadmanesh K, Arashkia A, Ghanei M. Protocol for Recovery of Measles Virus from Intact/Recombinant Antigenomic DNA. mjms. 2021; 24 (1) :45-54
URL: http://mjms.modares.ac.ir/article-30-52359-en.html
1- Baghyatollah Medical Sciences University
2- Department of Molecular Virology, Pasteur Institute of Iran, Tehran, Iran , Azadmanesh@pasteur.ac.ir
3- Department of Molecular Virology, Pasteur Institute of Iran, Tehran, Iran
4- Baghyatollah Medical Sciences University,Chemical Injuries Research Center
Abstract:   (457 Views)
Measles virus, negative-strand RNA viruses, has been known as an ideal candidate in oncolytic virotherapy.  Recombinant measles virus can encode genes of interests for reaching several aims. Replication efficiency of oncolytic virus in tumoral cells is a key parameter in efficient tumor eradication. Products of P gene (P/V/C) support measle virus to circumvent IFN 1 as the main response of innate immune system against viruses. But vaccine strains used in oncolytic therapy studies comprise several mutations in their P gene sequences. These mutations affect replication efficacy which cause attenuation of measles strains applicable in vaccination. So, arming vaccine strains with the wild type P gene is helpful to reach high virus titer. Here at this study, we have expanded a protocol with details for engineering and efficient recovery of measles virus for different aims.    
Full-Text [PDF 959 kb]   (135 Downloads)    
Article Type: Original Research | Subject: Biologic Products
Received: 2021/05/8 | Accepted: 2021/07/12

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.